Zhang Financial LLC Has $335,000 Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Zhang Financial LLC cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,200 shares of the company’s stock after selling 900 shares during the period. Zhang Financial LLC’s holdings in Teva Pharmaceutical Industries were worth $335,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of Teva Pharmaceutical Industries by 49.5% in the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after acquiring an additional 20,762,226 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 6.8% in the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after purchasing an additional 2,204,623 shares during the last quarter. State Street Corp grew its position in Teva Pharmaceutical Industries by 10.0% during the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock valued at $351,402,000 after buying an additional 1,778,268 shares during the period. Geode Capital Management LLC grew its position in shares of Teva Pharmaceutical Industries by 3.4% during the 3rd quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock valued at $157,571,000 after acquiring an additional 291,124 shares during the period. Finally, Janus Henderson Group PLC increased its position in Teva Pharmaceutical Industries by 7,945.2% in the third quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock worth $86,350,000 after buying an additional 4,732,374 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on TEVA. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday. Barclays upped their price objective on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Finally, StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.13.

Teva Pharmaceutical Industries Trading Up 1.3 %

Shares of NYSE:TEVA opened at $21.97 on Tuesday. Teva Pharmaceutical Industries Limited has a 12 month low of $10.86 and a 12 month high of $22.80. The company has a 50-day moving average price of $19.33 and a 200 day moving average price of $18.26. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.